HGS/GSK On Track To Initiate Lymphostat-B Phase III Study In 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Full Phase II study results show promise in treatment of lupus even though Lymphostat-B did not meet primary endpoints, the firm says.
You may also be interested in...
La Jolla Submits Riquent Application For Lupus In EU
The company is still pursuing a Phase III trial in the U.S. under a Special Protocol Assessment with FDA.
La Jolla Submits Riquent Application For Lupus In EU
The company is still pursuing a Phase III trial in the U.S. under a Special Protocol Assessment with FDA.
AstraZeneca Will Get Humira Royalty Revenue Through CAT Deal
AstraZeneca's acquisition of Cambridge Antibody Technology will give the firm royalty revenues from human monoclonal antibody technologies already licensed out by CAT, including Abbott's rheumatoid arthritis therapy Humira (adalimumab)